iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company. It was formed in 2008 and acquired intellectual property rights for a formulation of a fentanyl citrate nasal spray for patient-controlled analgesia. The company's founder, Chairman, and CEO, Mr. Eddy Lee, assembled a team of scientists with extensive expertise in drug development. Their research focused on creating an innovative drug delivery system that would enhance the safety, efficacy, ease of use, and absorption rate of drugs compared to existing platforms and administration routes. Today, iX Biopharma is a publicly-listed company in Singapore, specializing in the development and commercialization of innovative therapies. Their main focus is on improving the quality of life for individuals suffering from pain and other health conditions. The company's main products under development include Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, and WafeRest for improved sleep quality. iX Biopharma operates in the United States, Singapore, Australia, and China, with the majority of its revenue coming from the United States.
Headquarters
20 Collyer Quay, 11-07
Singapore; Singapore;
Postal Code: 049319
Contact Details: Purchase the Ix Biopharma Ltd report to view the information.
Website: http://www.ixbiopharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service